Home / About
A specialist bridge between the lab and the market.
Clementis exists to close the distance between scientific discovery and commercial value — with the rigor of a scientist and the discipline of a strategist.
Turning complex research into products the world can use.
Clementis Scientific Consulting is a high-level translational science and innovation strategy firm. We partner with organizations at the frontier of science to transform complex research into commercially viable, regulatory-aligned, and globally scalable solutions.
Our work sits precisely where breakthroughs stall: between a promising result and a launched product. We combine deep scientific expertise — nanotechnology, precision medicine, biomaterials, green chemistry — with the market intelligence, regulatory literacy, and program discipline needed to carry an innovation across the finish line. The firm is deliberately lean and founder-led, which means clients work directly with senior scientific judgment, not a hierarchy of intermediaries.
Our mission
To de-risk and accelerate the translation of frontier science into products that improve health, sustainability, and quality of life — everywhere they are needed.
Our vision
A world where the best science reaches the market on its merits — not lost to avoidable gaps in evidence, regulation, or commercial strategy.
Our promise
Honest, evidence-first counsel. If a programme is not ready — or not viable — you will hear it early, with the reasoning and the path to fix it.
Two founders. One standard.
Deep translational science, paired with a delivery system built to carry it — Clementis was founded by Dr. Velaphi Thipe and Azania Jameson.
Dr. Velaphi Thipe
Founder & Principal Consultant
- Ph.D. Chemistry — University of Missouri (Fulbright Scholar)
- MBA, Life-Sciences Innovation — University of Missouri
- M.Sc. Nanoscience — University of Johannesburg
- B.S. Biotechnology — University of Johannesburg
- Former Postdoctoral Fellow, Radiology
- Affiliate, Institute of Green Nanotechnology
Dr. Thipe’s career spans five countries and the full arc of translational science — from fundamental nanochemistry to registered, commercially available products.
Scientific specialization
Green nanotechnology and phytochemical synthesis, cancer-focused nanomaterials, radiolabeled nanoparticle imaging, and bioactive barrier technologies.
Cross-continental experience
Research, collaboration, and commercial delivery across South Africa, the United States, Brazil, India and Japan — with working knowledge of their regulatory environments.
Regulatory & IP track record
Secured ANVISA registration for a nanotechnology medical product; fluent across FDA, EMA, PMDA, CDSCO and SAHPRA pathways; inventor on pending U.S. patents.
Public recognition
Featured on KOMU 8 News and the TEDxCoMo stage for work advancing green nanotechnology and its real-world applications.
Azania Jameson
Co-Founder — Strategy & Operations
- Architect of the Clementis delivery system
- Research intelligence & evidence synthesis
- Engagement operations across four continents
- Runs the Insight Lab→Market programme
- The firm’s standard: no claim without its evidence
Azania is the systems half of Clementis — the delivery engine behind the science. Where Dr. Thipe brings the research and regulatory depth, she builds the machinery that turns it into decisions a client can act on.
Delivery architecture
Every engagement runs on systems Azania designed — evidence pipelines, decision frameworks and reporting cadences that let a deliberately lean firm operate with the reach of a large one.
Research intelligence
Horizon scanning and evidence synthesis behind every recommendation: literature, regulatory precedent and competitive signals, distilled to exactly what the decision needs.
Client experience
One point of continuity from first call to final deliverable — nothing handed off, nothing lost between stages.
The operating standard
No recommendation leaves Clementis without the evidence trail to defend it — the discipline the whole firm is built around.
Five commitments.
The principles that shape every engagement — and that clients can hold us to.
Scientific rigor
Every recommendation is grounded in evidence and mechanism — never hype.
Patient & user safety
Safe-by-design thinking sits at the centre of the science, not the margins.
Global scalability
We design for multiple markets and regulators from the very first decision.
Green technology
Cleaner chemistry and sustainable materials as a competitive advantage.
Cross-continental collaboration
Partnership across borders, disciplines, and institutions is how hard problems get solved.
What a specialist founder-led firm gives you.
A proven translational track record
Named programmes taken from concept through regulation to market — including an ANVISA-registered nanotechnology product and commercialized green-nano consumer lines.
Genuine regulatory reach
Working fluency across FDA, EMA, ANVISA, PMDA, CDSCO and SAHPRA — the multi-jurisdiction coordination most advisors cannot offer.
Multidisciplinary depth
Chemistry, nanoscience, biotechnology, and business strategy in one advisor — so the science and the commercial case are built together.
End-to-end perspective
From SAR optimization to launch sequencing, the whole path is held in view — no handoffs that drop the thread.
Remote-first, delivered across five countries.
Additional collaboration and research experience in Japan (PMDA). Time-zone-flexible, fully remote engagements.